Interventional Oncology Devices – Market Insights – Japan

The Japanese interventional oncology device market will grow slowly due to limited adoption of minimally invasive interventional oncology procedures, substantiated by Japanese guidelines and increasing developments in anticancer drugs, limiting the growth.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Japan from 2019 to 2032.

Overcoming the short-term consequences that COVID-19 pandemic has had on the interventional oncology devices, the market has begun to see recovery toward prepandemic levels.

How did the COVID-19 pandemic affect the different segments of the interventional oncology device market?

How has the recovery of impacted procedures been through 2022?

How will trends in interventional oncology device market evolve in the post pandemic era?

Alternative forms of treatment are commonly used to treat cancer in Japan.

What alternatives compete with interventional oncology devices, and how well do they complement or compete with the existing products?

How does the Japanese regulatory environment impact the use of these alternative treatments compared to interventional oncology devices?

Regulatory approval delays will impact the interventional oncology device market in Japan.

How have regulatory approval delays impacted the Japanese interventional oncology device market?

What new devices are anticipated to enter the Japanese market within the forecast period, and when are they expected to launch?

Gelatin sponge particles represent a large portion of the Japanese embolization device market, while radioembolization particles have yet to commercially launch.

What are the recent developments in the radioembolization space and how have those developments impacted estimated launch of these products?

Why are gelatin sponge particles used in Japan more than other geographies, and which competitors have benefited from this scenario?

Table of contents